FIRST QUARTER FINANCIAL RESULTS 2023

25 Apr 2023 07:55 CEST

Sales for the first quarter ended at MNOK 129.3 (MNOK 116.1), an increase of
11.3%. The Vascular business segment continues the positive development and
grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow
at 9.4% in NOK with a currency neutral decline of 3.7%. Currency neutral growth
of own products was 2.5%. Operating profit (EBIT) for the quarter ended at MNOK
33.5 (MNOK 33.4). Medistim establishes direct sales organizations in both Canada
and China this quarter. Cash position is down MNOK 3.3 due to inventory build up
and timing of sales for the quarter. The General Meeting decided a dividend of
NOK 4.50 per share, a total dividend payment of MNOK 82.2

More information:
Access the news on Oslo Bors NewsWeb site

588393_Quarterly Report Q1 2023-Final.pdf
588393_Medistim ASA Q1 2023 Presentation FINAL.pdf